From Casetext: Smarter Legal Research

Biosynexus v. Glaxo Group

Appellate Division of the Supreme Court of New York, First Department
May 17, 2007
40 A.D.3d 384 (N.Y. App. Div. 2007)

Opinion

May 17, 2007.

Order, Supreme Court, New York County (Bernard J. Fried, J.), entered March 14, 2006, which, insofar as appealed from, granted the motion by plaintiff Biosynexus, Inc. for a preliminary injunction, unanimously modified, on the facts, to vacate so much of the injunction as enjoins defendant Glaxo Group Limited (Glaxo) from "failing to exploit the intellectual property, including the confidential information, licensed by Biosynexus to Glaxo pursuant to the Collaborative Development [CDA] and License Agreement," and otherwise affirmed, without costs.

Before: Mazzarelli, J.P., Saxe, Williams, Buckley and McGuire, JJ.


The motion court did not err in concluding that Biosynexus was likely to prevail on its claim that Glaxo breached its fiduciary duties by impermissibly assigning to Medlmmune its rights and obligations under the CDA with respect to the monoclonal antibody technology and development program. In so finding, the motion court, aptly noting that both the CDA and License Agreement involve the granting of rights to various patents, appropriately looked to federal case law on standing in patent infringement cases ( see e.g. Bottlers Seal Co. v Rainey, 225 NY 369, 372, citing, inter alia, Waterman v Mackenzie, 138 US 252; see also Sybron Transition Corp. v Nixon, Hargrave, Devans Doyle, 770 F Supp 803, 809 [WD NY 1991]). Nor did the motion court err in concluding that the requisite showing of irreparable injury had been made, particularly given the difficulty of quantifying the losses Biosynexus would sustain as a result of Glaxo's breach of its fiduciary duties ( see Willis of NY. v DeFelice, 299 AD2d 240, 242). Moreover, relief should not be denied because of a short delay that did not cause a change of position or other prejudice ( see Hay Group v Nadel, 170 AD2d 398, 399-400). However, we vacate the injunction to the extent it affirmatively directs Glaxo's performance of the CDA, since in this respect the injunction "leaves the rights of the parties open to doubt and uncertainty" ( see SportsChannel Am. Assoc., v National Hockey League, 186 AD2d 417, 418). We have considered defendants' other arguments and find them unavailing.

[ See 11 Misc 3d 1062(A), 2006 NY Slip Op 50359(U).]


Summaries of

Biosynexus v. Glaxo Group

Appellate Division of the Supreme Court of New York, First Department
May 17, 2007
40 A.D.3d 384 (N.Y. App. Div. 2007)
Case details for

Biosynexus v. Glaxo Group

Case Details

Full title:BIOSYNEXUS, INC., Respondent, v. GLAXO GROUP LIMITED, Appellant, et al.…

Court:Appellate Division of the Supreme Court of New York, First Department

Date published: May 17, 2007

Citations

40 A.D.3d 384 (N.Y. App. Div. 2007)
836 N.Y.S.2d 126

Citing Cases

ARK PATENT INTL., LLC v. TARKSOL INTL., LLC

On the other hand, because the provisions of Exclusive License Agreement "involve the granting of rights to…

Sand Canyon Corp. v. Homeward Residential, Inc.

ionable breach of the confidentiality provision of the agreement to give persons entitled to see the loan…